Literature DB >> 12736188

Synthesis and anti-inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3.

Bifeng Gao1, Sonia C Flores, Jonathan A Leff, Swapan K Bose, Joe M McCord.   

Abstract

External surfaces of cells are normally protected by extracellular superoxide dismutase, SOD3, which binds to polyanions such as heparan sulfate. We constructed a fusion gene encoding a chimeric SOD consisting of the mature human mitochondrial SOD2 plus the COOH-terminal 26-amino acid heparin-binding "tail" from SOD3. This tail is responsible for the enzyme's affinity for endothelial surfaces. The fusion gene was expressed in Escherichia coli, and the fully active enzyme SOD2/3 was purified. Although native SOD2 has no affinity for heparin, SOD2/3 binds to a heparin-agarose column. In a rat model of acute lung injury induced by intratracheal instillation of IL-1, SOD2/3, SOD2, and denatured SOD2/3 showed 92%, 13.8%, and 0% reduction of lung leak, respectively. Only SOD2/3 prevented neutrophil accumulation. In the carrageenan-induced foot edema model in the rat, SOD2/3 reduced edema by 62% (P < 0.003) at a dose in which native SOD2 produced no significant effect. Thus SOD2/3 appears to have properties as a therapeutic anti-inflammatory agent that are greatly superior to other available forms of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12736188     DOI: 10.1152/ajplung.00374.2002

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  26 in total

Review 1.  Cystic fibrosis in adults: current and future management strategies.

Authors:  Brian M Morrissey; Bettina C Schock; Gregory P Marelich; Carroll E Cross
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

2.  A novel human derived cell-penetrating peptide in drug delivery.

Authors:  Jian Zhao; Peng Gao; Wei Xiao; Li-Qiang Fan; Fu-Jun Wang; Su-Xia Li; Jian-Wen Liu
Journal:  Mol Biol Rep       Date:  2010-11-16       Impact factor: 2.316

3.  Endothelial targeting of antibody-decorated polymeric filomicelles.

Authors:  Vladimir V Shuvaev; Marc A Ilies; Eric Simone; Sergei Zaitsev; Younghoon Kim; Shenshen Cai; Abdullah Mahmud; Thomas Dziubla; Silvia Muro; Dennis E Discher; Vladimir R Muzykantov
Journal:  ACS Nano       Date:  2011-08-23       Impact factor: 15.881

Review 4.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

5.  PECAM-targeted delivery of SOD inhibits endothelial inflammatory response.

Authors:  Vladimir V Shuvaev; Jingyan Han; Kevin J Yu; Shaohui Huang; Brian J Hawkins; Muniswamy Madesh; Marian Nakada; Vladimir R Muzykantov
Journal:  FASEB J       Date:  2010-09-27       Impact factor: 5.191

6.  The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man.

Authors:  F J F Broeyer; B E van Aken; J Suzuki; M J B Kemme; H C Schoemaker; A F Cohen; Y Mizushima; J Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2007-07-04       Impact factor: 4.335

7.  Redox pioneer: Professor Joe M. McCord.

Authors:  David M Schnell; Daret St Clair
Journal:  Antioxid Redox Signal       Date:  2013-11-12       Impact factor: 8.401

Review 8.  Extracellular superoxide dismutase and its role in cancer.

Authors:  Brandon Griess; Eric Tom; Frederick Domann; Melissa Teoh-Fitzgerald
Journal:  Free Radic Biol Med       Date:  2017-08-24       Impact factor: 7.376

Review 9.  Reactive species-induced microvascular dysfunction in ischemia/reperfusion.

Authors:  Hong Yu; Ted Kalogeris; Ronald J Korthuis
Journal:  Free Radic Biol Med       Date:  2019-03-05       Impact factor: 7.376

10.  Targeted detoxification of selected reactive oxygen species in the vascular endothelium.

Authors:  Vladimir V Shuvaev; Melpo Christofidou-Solomidou; Faiz Bhora; Karine Laude; Hua Cai; Sergei Dikalov; Evguenia Arguiri; Charalambos C Solomides; Steven M Albelda; David G Harrison; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2009-08-19       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.